Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

(NASDAQ:WGS) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx...

What is the market’s perception of the risk compared to peers and how might institutional investors adjust their positions? How could this legal development affect GeneDx's valuation metrics and short‑term price volatility? What is the likely timeline and potential financial exposure from the securities class action investigation?
Symbol: WGS
Lawsuits
16 days ago
Read more prnewswire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase...

Could the new data trigger any regulatory updates, reimbursement changes, or partnership opportunities that might impact the company's market valuation? What implications does the 12‑month OLE data have for Alnylam's future revenue forecasts compared to competing ATTR‑CM therapies? How will the presented long-term cardiovascular benefit data for Vutrisiran affect Alnylam's share price and trading volume?
Symbol: ALNY
Clinical trials
16 days ago
Read more businesswire

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

(NYSE:NVO) Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Card...

When will the STEER study results be reflected in regulatory submissions or labeling, and how might that timing influence the stock valuation in the near and long term? What impact will this cardiovascular outcome data have on Wegovy's market share and pricing relative to tirzepatide and other GLP‑1/dual‑agonist competitors? How will the 57% reduction in MACE risk for Wegovy versus tirzepatide affect Novo Nordisk's revenue forecasts and earnings guidance?
Symbol: NVO
Clinical trials
16 days ago
Read more globenewswire

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

(NYSE:NVO) Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Card...

What are the longer‑term implications for payer coverage, pricing strategy, and Novo Nordisk’s growth trajectory in the obesity/cardiovascular therapeutic space? Will this real‑world data cause a shift in market share away from tirzepatide and potentially impact Eli Lilly’s revenue forecasts? How will the 57% reduction in MACE with Wegovy versus tirzepatide affect Novo Nordisk’s share price in the short term?
Symbol: NVO
Clinical trials
16 days ago
Read more globenewswire

Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

(NYSE:NVO) Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight ...

What short‑term price volatility can we expect for Novo Nordisk’s stock and how should we position relative to competitor stocks like Eli Lilly? How might the efficacy data influence payer reimbursement policies and pricing strategies for Wegovy compared to tirzepatide? Will the 57% risk reduction for Wegovy vs tirzepatide boost Novo Nordisk’s market share in the obesity/diabetes space and drive a price rally?
Symbol: NVO
Clinical trials
16 days ago
Read more prnewswire

Gold Reserve Provides Update on U.S. Government’s Statement of Interest Supporting Venezuelan Opposition Government in Litigation Regarding Validity of 2020 PDVSA Bonds

(GRZ) PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that on August 29, 2025, the U.S. Government filed ...

How might the resolution of the PDVSA bond validity issue influence Gold Reserve's access to financing and its broader strategic position in the Venezuelan mining sector? What is the expected impact of the litigation outcome on Gold Reserve's share price and market valuation in the short to medium term? How will the U.S. Government's Statement of Interest affect the probability of a favorable outcome for Gold Reserve in the PDVSA bond litigation?
Symbol: GRZ
Litigation
17 days ago
Read more businesswire

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

(NYSE:NVS) Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of in...

Will the Phase IV V‑DIFFERENCE results trigger an immediate re‑rating or price target adjustment from analysts, and how might that influence short‑term stock volatility? What is the anticipated market share shift for Leqvio versus competing PCSK9 inhibitors and other cholesterol‑lowering therapies in the next 12‑24 months? How will the statistically significant LDL‑C goal achievement and reduced muscle pain side‑effects impact Novartis' projected revenue and earnings guidance for Leqvio?
Symbol: NVS
Clinical trials
17 days ago
Read more globenewswire